BACKGROUND: Few studies have characterized the role of sex on the incidence of invasive pneumococcal disease (IPD). We examined sex differences in rates of IPD, and trends after the introduction of pneumococcal conjugate vaccines (PCVs). METHODS: We used active population and laboratory-based IPD surveillance data from the Centers for Disease Control and Prevention Active Bacterial Core surveillance program (1998-2013) in Tennessee. Population-based rates of IPD by sex, race, age group, and PCV era were calculated. Rates were compared using incidence rate ratios. RESULTS: Throughout the study years, rates of IPD were higher in male than in female subjects, particularly in children <2 years and adults 40-64 years of age, with male subjects having IPD rates 1.5-2 times higher than female subjects. The proportions of comorbid conditions were similar in male and female subjects . Sex rate differences persisted after stratification by race. Although the introductions of 7-valent PCV (PCV7) and 13-valent PCV (PCV13) were associated with declines in IPD rates in both sexes, rates of IPD after PCV13 were still significantly higher in male than in female subjects among children and adults 40-64 and >74 years of age. CONCLUSIONS: Rates of IPD were generally higher in male than in female subjects. These sex differences were observed in different race groups and persisted after introduction of both PCVs.
BACKGROUND: Few studies have characterized the role of sex on the incidence of invasive pneumococcal disease (IPD). We examined sex differences in rates of IPD, and trends after the introduction of pneumococcal conjugate vaccines (PCVs). METHODS: We used active population and laboratory-based IPD surveillance data from the Centers for Disease Control and Prevention Active Bacterial Core surveillance program (1998-2013) in Tennessee. Population-based rates of IPD by sex, race, age group, and PCV era were calculated. Rates were compared using incidence rate ratios. RESULTS: Throughout the study years, rates of IPD were higher in male than in female subjects, particularly in children <2 years and adults 40-64 years of age, with male subjects having IPD rates 1.5-2 times higher than female subjects. The proportions of comorbid conditions were similar in male and female subjects . Sex rate differences persisted after stratification by race. Although the introductions of 7-valent PCV (PCV7) and 13-valent PCV (PCV13) were associated with declines in IPD rates in both sexes, rates of IPD after PCV13 were still significantly higher in male than in female subjects among children and adults 40-64 and >74 years of age. CONCLUSIONS: Rates of IPD were generally higher in male than in female subjects. These sex differences were observed in different race groups and persisted after introduction of both PCVs.
Authors: Nicholas D Walter; Thomas H Taylor; Scott F Dowell; Saundra Mathis; Matthew R Moore Journal: N Engl J Med Date: 2009-12-24 Impact factor: 91.245
Authors: Matthew R Moore; Ruth Link-Gelles; William Schaffner; Ruth Lynfield; Catherine Lexau; Nancy M Bennett; Susan Petit; Shelley M Zansky; Lee H Harrison; Arthur Reingold; Lisa Miller; Karen Scherzinger; Ann Thomas; Monica M Farley; Elizabeth R Zell; Thomas H Taylor; Tracy Pondo; Loren Rodgers; Lesley McGee; Bernard Beall; James H Jorgensen; Cynthia G Whitney Journal: Lancet Infect Dis Date: 2015-02-03 Impact factor: 25.071
Authors: Jonathan M Wortham; Elizabeth R Zell; Tracy Pondo; Lee H Harrison; William Schaffner; Ruth Lynfield; Ann Thomas; Arthur Reingold; Nancy M Bennett; Susan Petit; Deborah Aragon; Joseph Bareta; Billie A Juni; Monica M Farley; Bernard Beall; Matthew R Moore Journal: Clin Infect Dis Date: 2014-02-27 Impact factor: 9.079
Authors: Thomas R Talbot; Katherine A Poehling; Tina V Hartert; Patrick G Arbogast; Natasha B Halasa; Ed Mitchel; William Schaffner; Allen S Craig; Kathryn M Edwards; Marie R Griffin Journal: Pediatr Infect Dis J Date: 2004-08 Impact factor: 2.129
Authors: A Schuchat; T Hilger; E Zell; M M Farley; A Reingold; L Harrison; L Lefkowitz; R Danila; K Stefonek; N Barrett; D Morse; R Pinner Journal: Emerg Infect Dis Date: 2001 Jan-Feb Impact factor: 6.883
Authors: Carlos G Grijalva; J Pekka Nuorti; Patrick G Arbogast; Stacey W Martin; Kathryn M Edwards; Marie R Griffin Journal: Lancet Date: 2007-04-07 Impact factor: 79.321
Authors: Richard G Wunderink; Wesley H Self; Evan J Anderson; Robert Balk; Sherene Fakhran; Daniel Mark Courtney; Chao Qi; Derek J Williams; Yuwei Zhu; Cynthia G Whitney; Matthew R Moore; Anna Bramley; Seema Jain; Kathryn M Edwards; Carlos G Grijalva Journal: Clin Infect Dis Date: 2018-05-02 Impact factor: 9.079
Authors: Gertjan H J Wagenvoort; Elisabeth A M Sanders; Bart J Vlaminckx; Hester E de Melker; Arie van der Ende; Mirjam J Knol Journal: Euro Surveill Date: 2017-03-09